Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system.

[1]  C. Seger,et al.  An ultra-sensitive online SPE-LC-MS/MS method for the quantification of levonorgestrel released from intrauterine devices , 2011, Analytical and bioanalytical chemistry.

[2]  H. Concin,et al.  Use of the levonorgestrel-releasing intrauterine system: an Austrian perspective , 2009, Current opinion in obstetrics & gynecology.

[3]  L. Bahamondes,et al.  Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. , 2009, Contraception.

[4]  P. Thonneau,et al.  Contraceptive efficacy of intrauterine devices. , 2008, American journal of obstetrics and gynecology.

[5]  C. Lauritzen,et al.  Praktische Hormontherapie in der Gynäkologie , 2007 .

[6]  J. Griffin,et al.  The textbook of pharmaceutical medicine , 2005 .

[7]  R. Reid,et al.  Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. , 2005, Contraception.

[8]  I. Rauramo,et al.  A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. , 2001, Fertility and sterility.

[9]  R. Luoto,et al.  Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation‐wide study of 17,360 users , 2000, BJOG : an international journal of obstetrics and gynaecology.

[10]  V. Odlind,et al.  Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. , 1999, Acta obstetricia et gynecologica Scandinavica.

[11]  A. Kauppila,et al.  The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. , 1999, Fertility and sterility.

[12]  D. Mishell,et al.  Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. , 1997, Contraception.

[13]  D. Mishell,et al.  Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. , 1991, Contraception.

[14]  J. Toivonen,et al.  Protective Effect of Intrauterine Release of Levonorgestrel on Pelvic Infection: Three Years' Comparative Experience of Levonorgestrel- and Copper-Releasing Intrauterine Devices , 1991, Obstetrics and gynecology.

[15]  B. Xiao,et al.  Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. , 1990, Contraception.

[16]  A. Breckenridge,et al.  Clinical Pharmacokinetics of Oral Contraceptive Steroids , 1983, Clinical pharmacokinetics.

[17]  T. Luukkainen,et al.  TISSUE CONCENTRATIONS OF LEVONORGESTREL IN WOMEN USING A LEVONORGESTREL‐RELEASING IUD , 1982, Clinical endocrinology.

[18]  V. Odlind,et al.  Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. , 1994, Contraception.

[19]  I. Sivin,et al.  Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). , 1994, Fertility and sterility.

[20]  J. Toivonen.  The levonorgestrel-releasing intrauterine device. , 1994, Advances in contraceptive delivery systems : CDS.